The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Dr. Jack Cush reviews highlights from the past week on RheumNow.
If Congress changes or repeals the Affordable Care Act (ACA), which adults are at risk of losing health insurance?
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
A randomized trial of 537 knee osteoarthritis (OA) patients in the Duke Healthcare system has shown that patient- and provider interventions were no better than the usual standard of care.
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
The association between the use of proton pump inhibitors (PPIs), osteoporosis (OP) and OP-related fragility fractures has been a topic of ongoing discussion in rheumatology community.
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
A study of 90 consecutive male (50.3±11.1 years) with psoriatic arthritis (PsA) were were compared to 240 age matched controls without known cardiovascular (CV) diseases who underwent angiography for chest pain and/or multiple CV risk factors.
Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.
Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.